Trials / Not Yet Recruiting
Not Yet RecruitingNCT06356675
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Immune resistance after treatment, there is no standard treatment, one of the most important and the most effective measures is immune to combination therapy。Targeted angiogenesis therapy has always been the focus of research on the treatment of NSCLC patients with progressive disease after immunotherapy. From the mechanism of action, angiogenesis and immunosuppression are interrelated processes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | 200mg iv D1 Q3W |
| DRUG | Anlotinib | Anlotinib 12mg D1-12 Q3W |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2028-07-01
- Completion
- 2028-07-01
- First posted
- 2024-04-10
- Last updated
- 2024-04-10
Source: ClinicalTrials.gov record NCT06356675. Inclusion in this directory is not an endorsement.